Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abacavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | ALB | P02768 | 1/20 | 0.89 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.89 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ADCY5 | O95622 | 6/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abacavir SCHEMBL6896276 | 1.00 | NR1I2 (0.89) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL6896274 | 1.00 | NR1I2 (0.89) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL51933 | 1.00 | NR1I2 (0.89) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL6094190 | 0.96 | NR1I2 (0.82) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL1575900 | 0.96 | NR1I2 (0.85) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL6898682 | 0.96 | NR1I2 (0.85) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL6898685 | 0.96 | NR1I2 (0.85) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL1492161 | 0.96 | NR1I2 (0.85) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL28427025 | 0.96 | NR1I2 (0.89) | NR1I2ALBPDE4DABCB1BCHE | |
| Abacavir SCHEMBL1575076 | 0.96 | NR1I2 (0.89) | NR1I2ALBPDE4DABCB1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011333-B | Bifunctional molecules with antibody recruiting and human immunodeficiency virus entry inhibiting activity | 耶鲁大学 | 2021-03-19 | — | — | CN | claimed |
| EP-2640720-B1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | YALE UNIV INC (US) | 2018-10-17 | — | — | EP | claimed |
| US-9745334-B2 | Cytotoxic-drug delivering molecules targeting HIV (CDM-Hs), cytotoxic activity against the human immunodeficiency virus and methods of use | YALE UNIVERSITY (US) | 2017-08-29 | — | — | US | claimed |
| CN-107011333-A | There is the bifunctional molecule of inhibitory activity with recruitment antibody and to HIV entrance | 耶鲁大学 | 2017-08-04 | — | — | CN | claimed |
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | claimed |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | UNIV YALE (US) | 2016-03-24 | — | — | US | claimed |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY | 2015-03-26 | — | — | US | claimed |
| EP-2841107-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2015-03-04 | — | — | EP | claimed |
| CN-102753526-B | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIV GEORGIA | 2014-11-26 | — | — | CN | claimed |
| EP-2220046-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES INC (US) | 2014-06-18 | — | — | EP | claimed |
| CN-101702908-A | hiv-1 protease inhibitors | UNIVERISTY OF MASSACHUSETTS | 2010-05-05 | — | — | CN | claimed |
| EP-2139883-A2 | HIV-1 PROTEASE INHIBITORS | University of Massachusetts (US) | 2010-01-06 | — | — | EP | claimed |
| CN-101516369-A | Pyridinone diketo acids: inhibitors of HIV replication in combination therapy | UNIV GEORGIA (US) | 2009-08-26 | — | — | CN | claimed |
| CN-101309911-A | HIV-1 protease inhibitors, methods of making and methods of using the same | UNIV MASSACHUSETTS (US) | 2008-11-19 | — | — | CN | claimed |
| CN-101296901-A | HIV-1 protease inhibitors, and methods of making and using them | UNIV MASSACHUSETTS (US) | 2008-10-29 | — | — | CN | claimed |
| WO-2008118849-A2 | HIV-1 PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2008-10-02 | — | — | WO | claimed |
| EP-1937631-A2 | HIV-1 PROTEASE INHIBITORS | University of Massachusetts (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1937655-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | University of Massachusetts (US) | 2008-07-02 | — | — | EP | claimed |
| WO-2007002172-A2 | HIV-1 PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | claimed |
| WO-2007002173-A1 | HIV-1 PROTEASE INHIBITORS, AND METHODS OF MAKING AND USING THEM | UNIVERSITY OF MASSACHUSETTS (US) | 2007-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | CD4, HAVCR2, CD74 | NR1I2 2004/4885ALB 2728/4885PDE4D 4762/4885 |
| US-20160082102-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | NR1I2 1560/4885ALB 277/4885PDE4D 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.